Fibrosis Prediction Model

By using the model, you agree to the terms and conditions.

Reference: Sandra Collette, Laurence Collette, Tom Budiharto, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881 – 10882 ‘boost versus no boost’. European Journal of Cancer, 44 (2008), pp. 2587–2599.

Age (years)		26 – 78
Haematoma
Oedema
Menopausal status
Tamoxifen (for post-menopausal only)
Concomitant chemotherapy (not including adjuvant chemotherapy)
Radiation quality WBI
Type of Boost
Electron beam energy boost (MeV)		4 – 24
Maximum WBI dose known
Maximum WBI dose (Gy):		46 – 55